Metlifecare Limited — Director's Dealing 2017

Nov 16, 2017

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

ToNZX Limited andASX Limited:
Name of listedissuer:	MetlifecareLimited
Date this disclosuremade:	16November 2017
Date of last disclosure	8November 2017

A. Director or senior manager giving disclosure

A. Director or senior manager giving disclosure
Full name(s):	Tristram Milesvander Meijden
Name of listedissuer:	MetlifecareLimited
Name of related body corporate (ifapplicable):	N/A
Position heldin listedissuer:	FormerChief FinancialOfficer

B. Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

derivatives)
Class ofaffected quotedfinancialproducts:	Ordinary Shares
Nature of the affected relevant interest(s):	Registered Holder (as a trustee of the Westend Trust) and Beneficial Interest (as a beneficiary of the Westend Trust)
For that relevant interest-
Number held in class before acquisition or disposal:	26,299
Number held in class after acquisition or disposal:	0
Current registered holder(s):	Tristram Miles van der Meijden and Nicola Frances van der Meijden (as trustees of the WestendTrust)
Registeredholder(s) once transfers areregistered:	Unknown

C. Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

applicable)
Type ofaffected derivative:	N/A
Class ofunderlyingfinancialproducts:	N/A
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount ofunderlyingfinancialproducts (ifany):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative,-
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, thenature oftherelevantinterestinthe derivative:	N/A

D. Details of transactions giving rise to acquisition or disposal

Total numberoftransactions towhich noticerelates:	One
Details of transactions requiring disclosure-
Date oftransaction:	14 November 2017
Nature oftransaction:	Sale ofshares on market
Name of any other party or parties to the transaction (if known):	Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	$151,100.90
Numberof financialproducts towhichthe transaction related:	26,299
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of during a closed period:	The relevant interests were not disposed of during a “closed” period.
Whether prior written clearance was provided to allow the acquisitionordisposalto proceed during the closed period:	N/A
Date ofthe prior writtenclearance (ifany):	N/A

E. Summary of other relevant interests after acquisition or disposal:

Class ofquotedfinancialproducts:	Ordinary Shares
Nature of relevant interest:	Beneficial Owner (as a former participant in Metlifecare Limited’s senior executive restricted share plan pending cancellation of the shares under the plan).
For that relevant interest,-
Number held in class:	42,070
Current registered holder(s):	Metlifecare LTIP Trustee Limited
For a derivative relevant interest,-
Type of derivative:	N/A
Details of derivative-
The notional value of the derivative (if any) or the notional amount ofunderlyingfinancialproducts (ifany):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date ofthe derivative (ifany):	N/A
Expiry date ofthe derivative (ifany):	N/A
The price's specified terms (ifany):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative relevant interest,-
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, thenature oftherelevantinterestinthe derivative:	N/A

F. Certification

F. Certification
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date ofsignature:	16November 2017
Name and title of authorised person:	Andrew Peskett, General Counsel and Company Secretary